Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.9.4953

Genetic Factors, Viral Infection, Other Factors and Liver Cancer: An Update on Current Progress  

Su, Cheng-Hao (Department of Emergency Countermeasure and Information Management, Xiamen Center for Disease Control and Prevention)
Lin, Yong (Department of Infectious Disease Control, Xiamen Center for Disease Control and Prevention)
Cai, Lin (Department of Health Statistics and Epidemiology, School of Public Health, Fujian Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.9, 2013 , pp. 4953-4960 More about this Journal
Abstract
Primary liver cancer is one of the most common cancers at the global level, accounting for half of all cancers in some undeveloped countries. This disease tends to occur in livers damaged through alcohol abuse, or chronic infection with hepatitis B and C, on a background of cirrhosis. Various cancer-causing substances are associated with primary liver cancer, including certain pesticides and such chemicals as vinyl chloride and arsenic. The strong association between HBV infection and liver cancer is well documented in epidemiological studies. It is generally acknowledged that the virus is involved through long term chronic infection, frequently associated with cirrhosis, suggesting a nonspecific mechanism triggered by the immune response. Chronic inflammation of liver, continuous cell death, abnormal cell growth, would increase the occurrence rate of genetic alterations and risk of disease. However, the statistics indicated that only about one fifth of HBV carries would develop HCC in lifetime, suggesting that individual variation in genome would also influence the susceptibility of HCC. The goal of this review is to highlight present level of knowledge on the role of viral infection and genetic variation in the development of liver cancer.
Keywords
Viral infection; genetic variation; liver cancer;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Akkiz H, Bayram S, Bekar A, et al (2009). G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: casecontrol study. Cancer Epidemiol, 33, 261-4.   DOI   ScienceOn
2 Antoniou AC, Beesley J, McGuffog L, et al (2010). Common breast cancer susceptibility alleles and the risk of breast cancer of BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res, 70, 9742-54.   DOI   ScienceOn
3 Ataseven H, Bahcecioglu IH, Kuzu N, et al (2006). The levels of ghrelin, leptin, TNF-alpha, and IL-6 in lever cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm, 2006, 78380.
4 Abu Dayyeh BK, Yang M, Fuchs BC, et al (2011). A functional polymorphism in the epidermal growth factor gene is associated with the risk of hepatocellular carcinoma. Gastroenterology, 141, 141-9.   DOI   ScienceOn
5 Burchard J, Zhang C, Liu AM, et al (2010). MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol, 6, 402.
6 Bao Y, Yan Y, Xu C, et al (2013). MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett, 337, 226-36.   DOI   ScienceOn
7 Beasley RP, Lin CC, Hwang LY, et al (1981). Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 Men in Taiwan. Lancet, 318, 1129-33.   DOI   ScienceOn
8 Bihrer V, Waidmann O, Friedrich-Rust M, et al (2011). Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One, 6, e26971.   DOI
9 Chan HL, Hui AY, Wong ML, et al (2004). Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-8.   DOI   ScienceOn
10 Chan HL, Tse CH, Mo F, et al (2008). High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol, 26, 177-82.   DOI   ScienceOn
11 Chen K, Wei Y, Yang H, Li B (2011). Epidermal growth factor +61 G/A polymorphism and the hepatocellular carcinoma in a Chinese population. Genet Test Mol Biomarkers, 15, 251-5.   DOI   ScienceOn
12 Chen X, Zhang L, Chang Y, et al (2011). Association of TNFalpha genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a Han population. Int J Biol Markers, 26, 181-7.   DOI   ScienceOn
13 Cho LY, Yang JJ, Ko KP, et al (2011). Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer, 128, 176-84.   DOI   ScienceOn
14 Chu CM, Lin CC, Lin SM, Lin DY, Liaw YF (2012). Viral load, genotypes, and mutants in Hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci, 57, 232-8.   DOI   ScienceOn
15 Cougot D, Neuveut C, Buendia MA (2005). HBV induced carcinogenesis. J Clin Virol, 34, S75-8.
16 Gao ZY, Li T, Wang J, et al (2007). Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol, 42,761-8.   DOI
17 Du Cl, Wang JD (1998). Increased morbidity odds ratio of primary liver cancer and cirrhosis of the liver among vinyl chloride monomer workers. Occup Environ Med, 55, 528-32.   DOI
18 Ezzikouri S, El Feydi AE, Chafik A, et al (2007). The Pro variant of the p53 codon72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res, 37, 748-54.   DOI   ScienceOn
19 Gao C, Zhao HC, Li JT, Yao SK (2010). Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis. World J Gastroenterol, 16, 4467-75.   DOI
20 Giannitrapani L, Soresi M, Giacalone A, et al (2011). IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS, 15, 183-6.   DOI   ScienceOn
21 Gui JH, Tian YP, Wen XY, et al (2011). Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci, 120, 183-93.   DOI   ScienceOn
22 Hassan MM, Curley SA, Li D, et al (2010). Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer, 116, 1938-46.   DOI   ScienceOn
23 Hung CH, Lee CM, Wang JH, et al (2011). Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer, 128, 2344-52.   DOI   ScienceOn
24 Hung CH, Lu SN, Wang JH, et al (2011). Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antivir Ther, 16, 959-68.   DOI
25 International Agency for Research on Cancer (2009). Cancer Incidence and Mortality Worldwide in 2008. Lyon: IARC.
26 Hung CH, Wang JH, Hu TH, et al (2010). Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol, 16, 2265-71.   DOI
27 Imai Y, Tamura S, Tanaka H, et al (2010). Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat, 17, 185-91.   DOI   ScienceOn
28 International Agency for Research on Cancer (2008). Word Cancer Report 2008. Lyon: IARC.
29 Ito K, Tanaka Y, Orito E, et al (2006). T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis, 42, 1-7.   DOI
30 Jardi R, Rodriguez F, Buti M, et al (2001). Role of hepatitis B, C and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutation on viral replicative interference. Hepatology, 34, 404-10.   DOI   ScienceOn
31 Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.   DOI
32 Jorissen RN, Walker F, Pouliot N, et al (2003). Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res, 284, 31-53.   DOI   ScienceOn
33 Koberle V, Kronenberger B, Pleli T, et al (2013). Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer, Epub ahead of print.
34 Lemke LB, Rogers AB, Nambiar PR, Fox JG (2008). Obesity and non-insulin-dependent diabetes mellitus in Swiss-Webster mice associated with late-onset hepatocellular carcinoma. J Endocrinol, 199, 21-32.   DOI   ScienceOn
35 Kono S, Ikeda M, Tokudome S, Nishizumi M, Kuratsune M (1987). Cigarette smoking, alcohol and cancer mortality: a cohort study of male Japanese physicians. Jpn J Cancer Res, 78, 1323-8.
36 Kumar V, Kato N, Urabe Y, et al (2011). Genome-wide association study identifies a susceptibility locus for HCVinduced hepatocellular carcinoma. Nat Genet, 43, 455-8.   DOI   ScienceOn
37 Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N (2007). Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 14, 841-8.
38 Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20.   DOI   ScienceOn
39 Li P, Du Q, Cao Z, et al (2012). Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferonregulatory factor-1 (IRF-1). Cancer Lett, 314, 213-22.   DOI   ScienceOn
40 Li YJ, Xie Q, Lu FM, et al (2010). Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int, 30, 112-8.   DOI   ScienceOn
41 Liaw J, Marshall G, Yuan Y, et al (2008). Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. Cancer Epidemiol Biomarkers Prev, 17, 1982-7.   DOI   ScienceOn
42 Liu F, Li B, Wei Y, et al (2011). XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a metaanalysis. Liver Int, 31, 802-9.   DOI   ScienceOn
43 Lin SM, Yu ML, Lee CM, et al (2007). Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocelluar carcinoma. J Hepatol, 46, 45-52.   DOI   ScienceOn
44 Liu CJ, Chen BF, Chen PJ, et al (2006). Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carries. J Infect Dis, 193, 1258-65.   DOI   ScienceOn
45 Liu CJ, Chen BF, Chen PJ, et al (2006). Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis, 194, 594-9.   DOI   ScienceOn
46 Liu H, Ye L, Wang QW, Yan QX, Yu JM (2009). Effect of conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway. Chin Med J, 122, 460-5.
47 Long XD, Ma Y, Huang HD, et al (2008). Polymorphism of XRCC1 and the frequency of mutation in codon 249 of the p53 gene in hepatocellular carcinoma among Guangxi population, China. Mol Carcinog, 47, 295-300.   DOI   ScienceOn
48 Long XD, Ma Y, Wei YP, Deng ZL (2006). The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res, 36, 48-55.   DOI   ScienceOn
49 Loomba R, Yang HI, Su J, et al (2013). Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol, 177, 333-42.   DOI   ScienceOn
50 Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, et al (2007). Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer, 7, 162.   DOI
51 Lv L, Wang P, Zhou X, Sun B (2013). Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol, 34, 1451-9.   DOI   ScienceOn
52 Ma L, Teruya-Feldstein J, Weinberg RA (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449, 682-8.   DOI   ScienceOn
53 Mendy ME, Welzel T, Lesi OA, et al (2010). Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat, 17, 115-22.   DOI   ScienceOn
54 Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58.   DOI   ScienceOn
55 Ministry of health of the people's republic of China (2010). China health statistical yearbook in 2010. The first edition. Beijing, Peking union medical college press.
56 Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV (1998). Immune pathogenesis of hepatocellular carcinoma. J Exp Med, 188, 341-50.   DOI
57 Miyake, Y, Kobashi H, Yamamoto K (2009). Meta-analysis: the effect of interferon on development of hepatocellular carcinoma with patients with chronic hepatitis B virus infection. J Gastroenterol, 44, 470-5.   DOI
58 Mizuguchi Y, Mishima T, Yokomuro S, et al (2011). Sequencing and bioinformatics-based analyses of the mircoRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One, 6, e15304.   DOI   ScienceOn
59 Oh JK, Shin HR, Lim MK, et al (2012). Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and co-infected subjects in HBV endemic area:a community-based cohort study. BMC Cancer, 12, 452.   DOI
60 Mun HS, Lee SA, Kim H, et al (2011). Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocelluar carcinoma in patients with chronic genotype C infections. J Virol, 85, 123-32.   DOI   ScienceOn
61 Parkin DM (2006). The global health burden of infectionassociated cancers in the year 2002. Int J Cancer, 8, 3030-44.
62 Polesel J, Zucchetto A, Montella M, et al (2009). The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol, 20, 353-7.
63 Porkka KP. Pfeiffer MJ, Waltering KK, et al (2007). MicroRNA expression profiling in prostate cancer. Cancer Res, 67, 6130-5.   DOI   ScienceOn
64 Qu LS, Jin F, Huang XW, Ge YS (2010). Interferon-$\alpha$ therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol, 102, 796-801.   DOI   ScienceOn
65 Saito I, Miyamura T, Ohbayashi A, et al (1990). Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A, 87, 6547-9.   DOI
66 Saunders D, Seidel D, Alison M, Lyratzopoulos G (2010). Systematic review: the association between obesity and hepatocellular carcinoma- epidemiological evidence. Aliment Pharmacol Ther, 31, 1051-63.
67 Su H, Yang JR, Xu T, et al (2009). MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69, 1135-42.
68 Shafritz DA, Shouval D, Sherman HI, Hadziuannis SJ, Kew MC (1981). Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocelluar carcinoma. Studies in percutaneous liver biopsies and postmortem tissue specimens. N Engl J Med, 305, 1067-73.   DOI   ScienceOn
69 Soga K, Shibasaki K, Aoyagi Y (2005). Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology, 52, 1154-8.
70 Sopipong W, Tangkivanich P, Payungporn S, Posuwan N, Poovorawan Y. The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai Patients. Asian Pac J Cancer Prev, 14, 2865-9.
71 Sumbul AT, Akkiz H, Bayram S, et al (2012). p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a casecontrol study. Mol Biol Rep, 39, 1639-47.   DOI
72 Tanabe KK, Lemoine A, Finkelstein DM, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA, 299, 53-60.
73 Tatsukawa M, Takaki A, Shiraha H, et al (2011). Hepatitis B virus core promoter mutations G1613 and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer, 11, 458.   DOI
74 Thompson KJ, Swan RZ, Walling TL, et al (2013). Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular caricinoma in vivo. Surg Endosc, 27, 2782-91.   DOI   ScienceOn
75 Wei W, Liu F, Liu L, et al (2011). Distinct mutations in MLH1 and MSH2 genes in hereditary non-polyposis colorectal cancer (HNPCC) families from China. BMP Rep, 44, 317-22.   DOI   ScienceOn
76 Tomimaru Y, Eguchi H, Nagano H, et al (2010). MicroRNA-21 induces resistance to the anti-tumor effect of interferon-$\alpha$/5- fluorouracil in hepatocellular carcinoma cells. Br J Cancer, 103, 1617-26.   DOI   ScienceOn
77 Wang C, Wang X, Gong G, et al (2012). Increased risk of hepatocellular carcinoma in patients with diabete mellitus: A systematic review and meta-analysis of cohort studies. Int J Cancer, 130, 1639-48.   DOI   ScienceOn
78 Wang Z, Gao Q, Shi JY, et al (2013). Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma. PLoS One, 25, e62571.
79 Wu CF, Yu MW, Lin CL, et al (2008). Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis, 29, 106-12.   DOI
80 Wu D, Jiang H, Gu Q, Zhang D, Li Z (2013). Association between XRCC1 Arg399Gln polymorphism and hepatitis virus related hepatocellular carcinoma risk in Asian population. Tumour Biol, Epub ahead of print.
81 Yang JQ, Pan GD, Chu GP, et al (2008). Interferon-alpha restrains growth and invasive potential of hepatocellular induced by hepatitis B virus X protein. World J Gastroenterol, 14, 5564-9.   DOI
82 Yu ML, Lin SM, Chuang WL, et al (2006). A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther, 11, 985-94.
83 Yu MW, Yang SY, Pan IJ, et al (2003). Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst, 95, 1485-8.   DOI   ScienceOn
84 Yang YF, Zhao W, Zhong YD, et al (2009). Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat, 16, 265-71.   DOI   ScienceOn
85 Yin H, Xie F, Zhang J, et al (2011). Combination of interferon-$\alpha$ and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. Cancer Lett, 306, 34-42.   DOI   ScienceOn
86 Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6.   DOI   ScienceOn
87 Zhang CH, Xu GL. Jia WD, et al (2009). Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a metaanalysis of randomized controlled trials. Int J Cancer, 124, 2982-8.   DOI   ScienceOn
88 Zhang CH, Xu GL, Jia WD, et al (2011). Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a metaanalysis of randomized controlled trials. Int J Cancer, 129, 1254-64.   DOI   ScienceOn
89 Zheng JX, Zeng Z, Zheng YY, et al (2011). Role of hepatitis B virus base core and precore/core promoter mutations on hepatocellular carcinoma in untreated older genotype patients. J Viral Hepat, 18, e423-31.   DOI   ScienceOn
90 Zhang J, Yang Y, Yang T, et al (2010). MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppress cell proliferation and tumourigenicity. Br J Cancer, 103, 1215-20.   DOI   ScienceOn
91 Zhuang PY, Zhang JB, Zhang W, et al (2010). Long-term interferon-$\alpha$ treatment suppresses tumor growth but promotes metastasis capacity in hepatocelluar carcinoma. J Cancer Res Clin Oncol, 136, 1891-900.   DOI
92 Zhang KY, Imazeki F, Fukai K, et al (2007). Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci, 98, 1921-9.   DOI   ScienceOn
93 Zhao BH, Liu F, Liu S, Niu JJ, et al (2011). A case-control study of the association between human exposure to selected chlorinated pesticides and primary hepatocellular carcinoma. Epidemiology, 22, p S 145.
94 Zhou J, Yu L, Gao X, et al (2011). Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 29, 4781-8.   DOI   ScienceOn
95 Zhang HX, Zhai Y, Hu ZB, et al (2010). Genomoe-wide association study identifies 1p36.22 as new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carries. Nat Genet, 42, 755-8.   DOI   ScienceOn
96 Li Q, Li WW, Fan WB, et al (2012). Type 2 diabetes and hepatocellular carcinoma: A case-control study in patients with chronic hepatitis B. Int J Cancer, 131, 1997-202.
97 Howlader N, Noone AM, Krapcho M, et al (2011). EER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site.
98 Adami HQ, Hsing AW, McLaughlin JK, et al (1992). Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer, 51, 898-902.   DOI
99 Koh WP, Wang R, Jin A, Yu MC, Yuan JM (2013). Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer, 108, 1182-8.   DOI   ScienceOn